SAN FRANCISCO and WALTHAM, Mass. - Apogee (NASDAQ:APOG) Therapeutics, Inc. (NASDAQ: APGE), a biotechnology firm focused on developing treatments for inflammatory conditions, announced today its intention to launch a public offering of common stock valued at approximately $350 million. The company also intends to provide underwriters with a 30-day option to purchase up to an additional $52.5 million of shares.
The offering, which is subject to market conditions and other factors, has no confirmed completion date or definitive size at this point. Apogee is the sole provider of the securities in question. The joint book-running managers for the offering are Jefferies, BofA Securities, Goldman Sachs & Co (NYSE:GS). LLC, TD Cowen, and Stifel.
Apogee's securities have been registered with the Securities and Exchange Commission (SEC) through a filing, but the registration statement has not yet become effective. Therefore, the securities cannot be sold, nor can offers to buy be accepted until the registration statement is effective.
The company is currently developing biologics for various diseases, including atopic dermatitis, chronic obstructive pulmonary disease, and asthma. Its two lead programs, APG777 and APG808, target atopic dermatitis and chronic obstructive pulmonary disease, respectively.
The press release includes forward-looking statements regarding the proposed offering's terms, size, and completion. However, these statements are subject to change based on numerous factors, including global economic conditions and the results of Apogee's research and development activities.
Investors are cautioned not to place undue reliance on these forward-looking statements, which reflect the company's position as of the date of the press release. Apogee's actual results may differ materially due to a variety of risks and uncertainties, as detailed in its filings with the SEC.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.